Eric de Rus schreef op 6 juni 2020 18:57:
Bron: Interfax
Moscow. June 6th. INTERFAX.RU - The Russian Ministry of Health has registered another drug for the treatment of complications of a new coronavirus infection for use in Russia, the agency’s press service said on Saturday.
"The drug Levilimab (trade name" Ilsira ") has become the second drug registered under the accelerated procedure," the press service reported to Interfax.
The new drug is indicated for patients with severe disease, when one of the complications of COVID-19, the so-called cytokine storm, develops.
A cytokine storm is an excessive inflammatory reaction of the body to the introduction of the virus, which leads to damage to tissues and organs, in particular, lung tissue, to a severe course of infection with a possible fatal outcome.
As stated in the Ministry of Health, preventing the development of a cytokine storm is extremely important in the treatment of COVID-19.